Interleukin-2 inhibits proliferation of HPV-associated tumor cells and halts tumor growth in vivo

Casaña, Patricia Hernández; Hernández, Héctor Hernández y; Araña, M.J.

doi:10.1016/s0006-291x(02)02715-8

Cited by 7 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…IL2 is known to inhibit proliferation and growth of various cancer cells (Casana et al, 2002), and thus a downregulation of a subunit of its receptor may be one additional mechanism whereby growth factors in general promote growth. All four growth factors were shown to downregulate the expression of CDH11.…”

Section: Ewsr1mentioning

confidence: 99%

Identification of novel growth factor-responsive genes in neuroendocrine gastrointestinal tumour cells

et al. 2005

View full text Add to dashboard Cite

Targeting growth-regulatory pathways is a promising approach in cancer treatment. A prerequisite to the development of such therapies is characterisation of tumour growth regulation in the particular tumour cell type of interest. In order to gain insight into molecular mechanisms underlying proliferative responses in neuroendocrine (NE) gastrointestinal (GI) tumours, we investigated gene expression in human carcinoid BON cells after exposure to gastrin, hepatocyte growth factor (HGF), pituitary adenylate cyclaseactivating polypeptide or epidermal growth factor. We particularly focused on gastrin-and HGF-induced gene expression, and identified 95 gastrin-and 101 HGF-responsive genes. The majority of these genes are known mediators of processes central in tumour biology, and a number of them have been associated with poor prognosis and metastasis in cancer patients. Furthermore, we identified 12 genes that were regulated by all four factors, indicating that they may be universally regulated during NE GI tumour cell proliferation. Our findings provide useful hypotheses for further studies aimed to search for new therapeutic targets as well as tumour markers in NE GI tumours.

show abstract

Section: Ewsr1mentioning

confidence: 99%

Identification of novel growth factor-responsive genes in neuroendocrine gastrointestinal tumour cells

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Interleukin-2 (IL-2) is a cytokine produced endogenously by activated T cells and is commercially available as aldesleukin (Proleukin), a human recombinant product (El mir et al, 2001). IL-2 is effective in the treatment of a variety of malignancies, including renal cell carcinoma and melanoma, because it has both immune-modulating and antitumor properties (Casana et al, 2002). A variety of IL-2 doses and schedules have been studied; however, high dose IL-2 administered as a single agent has proven to be one of the most effective regimens for metastatic renal cell carcinoma and melanoma to date.…”

Section: Resultsmentioning

confidence: 99%

Evaluation of antitumour action of Ganoderma lucidum extract in hepatocarcinoma mice

Wu¹,

Guan²,

Jianzhong³

et al. 2012

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

The present study shows the protective effects of the Ganoderma lucidum aqueous crude extract (GLE) against mice liver cancer. The mice were randomized into four groups, namely, controls and tumor bearers that were G. lucidum extract-treated or untreated. Tumor bearers were inoculated intraperitoneally (ip) with 108 Yoshida AH-130 ascites hepatoma cells, whereas the controls received saline alone. The treatment began 1 day after tumor cell inoculation, and continued for 14 days. Administration of G. lucidum extract reduced the tumour weight of G. lucidum-treated groups in a dose dependent way (1.627 ± 0.135, 1.142 ± 0.144 versus 2.163 ± 0.316) as compared to model control group. The inhibition rate was 24.84, and 47.31 by G. lucidum extract administration at concentrations of 200 and 400 mg/kg body weight, respectively. Results of this investigation justify continuing with further studies of G. lucidum extract components to develop chemoprevention strategies as an option in the treatment of cancer.

show abstract

“…Table 1 displays the results obtained by other groups and Table 2 results by our group. Both Tables show that local IL-2 therapy may be effective in a broad range of tumor types such as carcinomas [ 6 , 33 , 42 , 50 , 58 , 64 , 72 , 73 , 87 , 94 , 96 ], sarcomas [ 10 , 16 – 18 , 86 ], a myeloma [ 69 ], lymphomas [ 10 , 66 , 67 ], leukemia [ 10 ], a mastocytoma [ 68 ], and HPV associated tumor [ 21 ].…”

Section: Therapeutic Effects Of Local Il-2 Therapy Against Transplantmentioning

confidence: 99%

Local therapy of cancer with free IL-2

Otter

Jacobs

Battermann³

et al. 2008

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

Interleukin-2 inhibits proliferation of HPV-associated tumor cells and halts tumor growth in vivo

Cited by 7 publications

References 27 publications

Identification of novel growth factor-responsive genes in neuroendocrine gastrointestinal tumour cells

Identification of novel growth factor-responsive genes in neuroendocrine gastrointestinal tumour cells

Evaluation of antitumour action of Ganoderma lucidum extract in hepatocarcinoma mice

Local therapy of cancer with free IL-2

Contact Info

Product

Resources

About